Company intelligence / Profile preview

GEMMABio

Philadelphia, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

GEMMABio has developed three FDA-approved gene therapies for rare diseases using AAV vectors, with about 40 active pipeline programs and recent success in international partnerships to expand clinical access, including a $100 million R&D/manufacturing deal with Brazil’s Fiocruz[2][3][4][5].

Therapeutic areas: NeurologyRare Diseases
Modalities: Gene therapyBiologicAAV-based gene therapy
Industry: Biotech

Partnerships

Fiocruz (Brazilian Ministry of Health, $100M gene therapy partnership)[5]

Beyond the preview

Go deeper on GEMMABio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GEMMABio.

Explore the full profile